According to OpenAI, the company is investing in Merge Labs, a startup focused on developing brain-computer interfaces (BCIs). The investment aims to support the development of new interfaces that bridge biological and artificial intelligence.
OpenAI states that the goal of this partnership is “to maximize human ability, agency, and experience” through these emerging technologies. Brain-computer interfaces represent a growing field at the intersection of neuroscience and AI, enabling direct communication pathways between the brain and external devices.
The announcement did not specify the investment amount or detailed technical specifications of Merge Labs’ BCI technology. This move positions OpenAI alongside other technology companies exploring the convergence of human cognition and artificial intelligence systems.
The investment represents OpenAI’s expansion beyond its core focus on large language models and generative AI into the neurotechnology sector, though the company provided limited details about how this investment aligns with its broader strategic objectives or timeline for development.